Emerging Equities has added a 3 new picks to the “Hot Stock Watch” list for 8/2
Emerging Equities has added a 3 new picks to the “Hot Stock Watch” list for August 2, 2004 – RIGL, NTMD, MRKL
For Immediate Release
August 2, 2004
Emerging Equities has added a 3 new picks to the “Hot Stock Watch” list for August 2, 2004 – RIGL, NTMD, MRKL
TORONTO, ON, August. 2, 2004
Hot stock watch – Full coverage available to premium members.
(RIGL) Rigel's R112 Demonstrates Robust Effect in Reducing Symptoms of Allergic Rhinitis in Large Phase II Clinical Trial
2004-08-02 07:25 ET - News Release
SOUTH SAN FRANCISCO, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced the successful results of a Phase II clinical study evaluating the use of R112, for the treatment of the symptoms of allergic rhinitis. The day one data indicated that R112 reduced the Global Nasal Allergy Symptom Score by 7.0 points (38%) versus 5.4 points (29%) for placebo (p=0.0005), an absolute difference of 9%, and a relative improvement over placebo of 24%. Results on day two were of similar magnitude (p=0.0016).
The randomized, placebo-controlled "Park" study enrolled 319 patients who were verified to suffer from allergic rhinitis. The primary objective of the study was to measure safety and efficacy of R112 as an intranasal treatment for allergic rhinitis. The Global Nasal Allergy Symptom Score used in the study showed a greater than 20% relative improvement for R112 over placebo (an absolute difference of 9% over placebo) and up to 38% improvement for R112 from baseline measurements (prior to drug initiation). There were no significant drug-related adverse events reported in the trial, and adverse event frequencies were indistinguishable from placebo. As early as the 30-minute time interval after dosing, R112 showed a statistically significant improvement in symptom scores over placebo, demonstrating a rapid onset of action in symptom improvement. Furthermore, these beneficial effects lasted throughout the entire measurement period until the end of the park day. In particular, symptoms most closely associated with chronic nasal congestion (e.g. stuffy nose) were dramatically improved with R112 over placebo.
"These results support R112 as a potential new treatment option for the millions of sufferers with this chronic condition," said Eli Meltzer, M.D., Allergy & Asthma Medical Group and Research Center. "Many patients with allergic rhinitis have tried multiple medications with inadequate symptom relief. R112 represents an entirely different therapeutic modality and in this study demonstrated a broad and comprehensive biological effect, excellent safety and a rapid onset of action."
"R112 shows excellent promise in the treatment of allergic rhinitis, and we plan to continue our clinical evaluation of it in phase III trials," stated James M. Gower, chairman and CEO of Rigel. "Our approach of using primary human cells, in this case human mucosal mast cells, to identify and validate targets critical to human disease mechanisms has enabled us to discover and design a class of molecules which work via a novel mechanism, blocking syk kinase. We believe this is an important advance in treating allergic diseases of the respiratory pathway, including both allergic rhinitis and allergic asthma."
(NTMD) NitroMed Names Mark Pavao as Senior Vice President of Sales and Marketing
2004-08-02 09:18 ET - News Release
LEXINGTON, Mass. -- (Business Wire) -- Aug. 2, 2004
Company Accelerates Planning for Anticipated 2005 Launch of BiDil(R)
NitroMed, Inc. (NASDAQ: NTMD) today announced the appointment of Mark H. Pavao as Senior Vice President of Sales and Marketing. Mr. Pavao will be responsible for building the Company's marketing and sales operations. In this newly created position, he will oversee the implementation of the Company's commercialization strategy for BiDil, its lead product in development for the treatment of heart failure in African Americans. Mr. Pavao will be responsible for ensuring the integration of the Company's clinical, regulatory, manufacturing, and marketing and sales resources. He joins NitroMed from Bristol-Myers Squibb where he was Vice President, Neuroscience Marketing. Because of the significant survival benefit seen with BiDil, NitroMed prematurely halted its confirmatory phase III clinical trial of the drug. The action was taken on July 19th and followed the unanimous recommendations of both the trial's independent Data and Safety Monitoring Board (DSMB) and its Steering Committee. BiDil is an orally administered nitric oxide enhancing medicine which combines isosorbide dinitrate and hydralazine. Over 1,000 patients in 170 sites across the United States were enrolled in the double blind placebo controlled trial, known as the African American Heart Failure Trial or A-HeFT. The Association of Black Cardiologists is a joint sponsor of the study.
"Our recent news indeed accelerates our expected timeline to commercialization. We are fortunate to have Mark on board at such an exciting and important time for us. Mark has an outstanding track record in delivering exceptional results. His addition to NitroMed's
senior management team signals our commitment to building an integrated pharmaceutical company with sales and marketing
capabilities in preparation for our anticipated launch of BiDil in 2005, assuming it is approved by the FDA. Mark brings a unique
appreciation of our goals and shares our commitment to address the disproportionate cardiovascular burden borne by African Americans," said Michael D. Loberg, Ph.D., President and C.E.O. of NitroMed. Mr. Pavao began his career in the pharmaceutical industry at SmithKline Beecham Pharmaceuticals, where he spent more than ten years in positions of increasing management responsibility, with major roles in marketing, sales and managed care, including significant experiences managing strategic alliances and disease management programs. Most recently, as Vice President, Marketing for the Neuroscience Division at Bristol-Myers Squibb, Mr. Pavao was responsible for the launch of Abilify(R), which was recognized as one of the top ten pharmaceutical product launches based on sales achieved in the first year on the market. Prior to that, Mr. Pavao was Vice President, Sales and Marketing at Helios Health, Inc., a venture-backed company that installed and maintained Internet-connected patient education kiosks in doctors' waiting rooms. Mr. Pavao holds an M.B.A. from The Wharton School, University of Pennsylvania and a B.A. with highest honors from the University of North Carolina at Chapel Hill.
About NitroMed, Inc.
NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally occurring molecule nitric oxide. The Company uses its expertise in nitric oxide biology and chemistry in an effort to develop both novel drugs, as well as safer, more effective versions of existing drugs. Research and development efforts focus on major diseases that are characterized by a deficiency in nitric oxide, such as cardiovascular and inflammatory diseases. BiDil(R), the Company's lead product in development, is an orally administered nitric oxide-enhancing medicine being investigated for the treatment of heart failure in African Americans. Because of the significant survival benefit seen with BiDil, NitroMed prematurely halted its confirmatory phase III clinical trial of the drug. The action was taken on July 19, 2004 and followed the unanimous recommendations of both the trial's independent Data and Safety Monitoring Board (DSMB) and its Steering Committee. Over 1,000 patients in 170 sites across the United States were enrolled in the double blind placebo controlled trial, known as the African American Heart Failure Trial or A-HeFT. The Association of Black Cardiologists is a joint sponsor of the study. Collaborative partnerships are a key element of the Company's business strategy. NitroMed has agreements with Merck to jointly develop nitric oxide COX-2 inhibitors and with Boston Scientific to jointly develop nitric oxide coated cardiovascular stents.
HomelandDefenseStocks.com Reports: More Billions for Biodefense -- Are Vaccines the Answer?
2004-07-29 13:07 ET - News Release
Also News Release (U-AEMD) AETHLON MEDICAL INC
POINT ROBERTS, WA -- (MARKET WIRE) -- 07/29/04
http://media.marketwire.com/attachments/200403/175670_HDSFinalLogo_Red_medium.jpg
www.HomelandDefenseStocks.com, (HDS) an investment news portal for the Homeland Defense and Security Sector, reports on treatments and vaccines in an exclusive featured article "More Billions for Biodefense -- Are vaccines the answer?" following the recent signing of Project BioShield into law by the President. Project BioShield, a $5.6 Billion bill that will stockpile new vaccines and develop countermeasures to bioterrorism attacks, will fuel demand for biological and chemical weapons detection and protection solutions. Within the biodefense community the question is being raised whether we should spend more on post-exposure treatments?
HDS does not make recommendations, but offers a unique, free information portal to investors to research news, articles, interviews and a growing list of participating public companies and featured profiled companies within the sector including: Aethlon Medical, Inc. (OTC BB: AEMD) and Markland Technologies, Inc. (OTC BB: MRKL).
More Billions for Biodefense -- Are vaccines the answer?
By Allen Gibson, HomelandDefenseStocks.com
With the recent signing by the President of the Project Bioshield Act of 2004, the federal government has authorized $5.6 Billion dollars in spending over the next ten years to increase American's security from biological attack.
Already, the government has purchased smallpox and anthrax vaccines -- 75 million doses in the case of anthrax -- as a key part of the Bioshield initiative. But is this a case of "fighting the last war" or defending against the last terror attack?
A report out of the University of Pittsburgh suggests that the life sciences are at the beginning of a revolutionary period. Scientific understanding of living systems and how to manipulate them is expanding exponentially. The report, from The Center for Biosecurity at the U of P, suggests our strategy should be "an ambitious and aggressive scientific research, development, and production (R & D & P) program that delivers the diagnostic technologies, medicines, and vaccines needed to counter the range of bioweapons agents."
...The doctors in charge of education for the National Center for Biodefense argue that less money should be spent on vaccine purchase and development, and more on post-exposure treatments.
Vaccines, say Drs. Ken Alibek and Charles Bailey, aren't going to be effective for civilian populations, since no one can know which specific agent to guard against, and the drugs must be administered in advance to be effective. Also, they say in a letter to the editor of the Biosecurity and Bioterror newsletter, it is far easier and takes fewer years to develop a weapons-grade disease than to produce a vaccine against it.
The immediate relevancy of programs other than vaccines was vividly demonstrated this July, when the FBI announced that Ricin compound was introduced into some baby food jars on the west coast. Minute amounts of Ricin can be fatal. The gaseous form of Ricin was used in the deadly Tokyo subway attacks a few years ago. And no vaccine or cure presently exists. Which means that new, non-vaccine; treatments are needed now, and will be needed in the future.
One example of how biotech can be repurposed to address the bioterror threat comes from Aethlon Medical (OTC BB: AEMD), who created a "Hemopurifier" machine to strip viruses and toxins out of the blood of infected patients. Originally designed to treat HIV and Hep C, the company is now working with the National Center for Biodefense at George Mason University to develop filtration devices that could be used by both the military and civilian populations against Class A bioterror agents. The Company will use new FDA rules to test the devices on animal species and extrapolate safety data for humans, since human tests are obviously not practicable.
Full article: www.HomelandDefenseStocks.com/Companies/HomelandDefense/Articles/Biodefense.asp
HDS Featured Companies: Biological and chemical weapons detection and medical countermeasures: HDS is compensated by featured companies as disclosed below.
Aethlon Medical, Inc. (OTC BB: AEMD) www.AethlonMedical.com is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. The Company is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism.
Markland Technologies, Inc. (OTC BB: MRKL) www.marklandtech.com. is positioned in the chemical detection sector with its Shipboard Automatic Chemical Agent Detection and Alarm System (ACADA). The ACADA is an automatic chemical agent alarm system capable of detecting, warning and identifying blister and nerve agents simultaneously. The ACADA is man-portable, operates independently after system start-up, provides an audible and visual alarm, and provides communication interface to support battlefield automation systems.
HomelandDefenseStock.com list of public companies in the sector: www.InvestorIdeas.com/Companies/HomelandDefense/Articles/StockList.asp
Disclaimer: ECON Corporate Services is the owner of the domain www.HomelandDefenseStocks.com. The site does not make recommendations but offers an information portal to investors to research news, articles, and recent research. The site is currently compensated for by its "featured companies." Markland Technologies, Inc. currently pays ECON $10,000 per month. Markland has issued shares to ECON in the past and these payments are for the purpose of including Markland in articles and other promotions. Aethlon Medical, mentioned in this article, pays $3000 per month plus restricted shares equivalent to $5000 per month.
Emerging Equities currently offers this service to premium members. Join today and receive 50 “Hot Stock Watch” alerts per year.
Emerging Equities provides investors with featured stock picks and research reports. All stock picks are publicly traded on the Nasdaq, OTCBB, TSE, or TSX Venture Markets. Our focus is on short and long term prospects within a 1 to 6 month time frame. Majority of our researched stocks are under $1.00. All picks are research analyzed, and featured when a stock appears poised for growth...
Become an unlimited access Premium Member for only $7 per month! Visit www.ee.aslcapitalcorp.com for more info.
ASL Capital Corp website can be visited at www.aslcaptialcorp.com
Emerging Equities website can be visited at www.ee.aslcapitalcorp.com
Information contained herein is the opinion of Emerging Equities ("EE") and is intended to be used strictly for informational purposes. You should be aware that EE attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, EE does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of EE's analyses and/or parties related to those companies. EE also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC and/or OSC, BSC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
EE, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a EE analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an EE opinion, recommendation or analysis. Information regarding companies which EE has opined upon is normally available from many sources including the subject company's filings with the SEC and/or OSC, BSC and various press releases issued by the company. You should be aware that EE is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating EE's statements regarding a company. EE has not been compensated for publication of this release. EE's officers and directors reserve the right to buy shares of the company discussed in this opinion and may profit in the event those shares rise in value. Emerging Equities is a division of ASL Capital Corp.
Contact: ASL Capital Corp 647.880.5400 sales@ee.aslcapitalcorp.com
SOURCE: www.ee.aslcapitalcorp.com
|
|